Derrell Porter

CIK: 0001706400

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)3 (33.3%)

Position reduction

Option Exercises (M)2 (22.2%)

Derivative conversions

Awards (A)4 (44.4%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

ABOS

Acumen Pharmaceuticals, Inc.

Director

PASG

Passage BIO, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (9 total)

ABOS
Acumen Pharmaceuticals, Inc.
Jun 17, 2026
Sale(S)
Direct
13K shares at avg. $2.33$30K
ABOS
Acumen Pharmaceuticals, Inc.
Jun 17, 2026
Exercise(M)
Direct
13K shares at avg. $1.07$14K
ABOS
Acumen Pharmaceuticals, Inc.
Jun 16, 2026
Sale(S)
Direct
12.8K shares at avg. $2.33$30K
ABOS
Acumen Pharmaceuticals, Inc.
Jun 15, 2026
Exercise(M)
Direct
6.5K shares at avg. $1.07$7K
ABOS
Acumen Pharmaceuticals, Inc.
Jun 15, 2026
Sale(S)
Direct
6.5K shares at avg. $2.35$15K
ABOS
Acumen Pharmaceuticals, Inc.
Jun 3, 2026
Award(A)
Direct
35.5K shares-
PASG
Passage BIO, Inc.
May 19, 2026
Award(A)
Director Stock Option (right to buy)
Direct
10.5K shares-
ABOS
Acumen Pharmaceuticals, Inc.
Jun 4, 2025
Award(A)
Direct
12.8K shares-
PASG
Passage BIO, Inc.
May 28, 2025
Award(A)
Director Stock Option (right to buy)
Direct
201.9K shares-

		Type	Shares	Price		Ownership
Jun 17, 2026	ABOS Acumen Pharmaceuticals, Inc.	Sale(S)	13,040	$2.33	$30,318	Direct
Jun 17, 2026	ABOS Acumen Pharmaceuticals, Inc.	Exercise(M)	13,040	$1.07	$13,953	Direct
Jun 16, 2026	ABOS Acumen Pharmaceuticals, Inc.	Sale(S)	12,800	$2.33	$29,773	Direct
Jun 15, 2026	ABOS Acumen Pharmaceuticals, Inc.	Exercise(M)	6,460	$1.07	$6,912	Direct
Jun 15, 2026	ABOS Acumen Pharmaceuticals, Inc.	Sale(S)	6,460	$2.35	$15,149	Direct
Jun 3, 2026	ABOS Acumen Pharmaceuticals, Inc.	Award(A)	35,500	-	$0	Direct
May 19, 2026	PASG Passage BIO, Inc.	Award(A) Director Stock Option (right to buy)	10,539	-	-	Direct
Jun 4, 2025	ABOS Acumen Pharmaceuticals, Inc.	Award(A)	12,800	-	-	Direct
May 28, 2025	PASG Passage BIO, Inc.	Award(A) Director Stock Option (right to buy)	201,857	-	-	Direct

1-9 of 9 transactions

About Porter Derrell

Porter Derrell (SEC CIK 0001706400) files insider reports with the SEC as Director of Acumen Pharmaceuticals, Inc. (ABOS) and Director of Passage BIO, Inc. (PASG).

Signal8 holds 5 ownership filings by Porter Derrell, all Form 4s, filed between May 30, 2025 and Jun 17, 2026. Those filings report 9 transactions, from May 28, 2025 to Jun 17, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Porter Derrell's filings is in NEWTON, MA.

Recent filings by Porter Derrell

Jun 17, 2026: Open-market sale of ABOS shares (Form 4, code S).
Jun 17, 2026: Option exercise of ABOS shares (Form 4, code M).
Jun 16, 2026: Open-market sale of ABOS shares (Form 4, code S).
Jun 15, 2026: Option exercise of ABOS shares (Form 4, code M).
Jun 15, 2026: Open-market sale of ABOS shares (Form 4, code S).

Other insiders filing for Acumen Pharmaceuticals, Inc. (ABOS)

How to read Form 4 transaction codes